Clinical Trial ProgressCompletion of the second cohort marks a significant milestone for the company, indicating progress in the study.
Financial StabilitySensorion ended the year with EUR77m in cash after two successful funding rounds, ensuring financial stability.
Safety And TolerabilityThe SENS-501 gene therapy product and surgical procedure were well-tolerated by all treated patients, with no serious adverse events.